Personalized therapy has become more and more important nowadays, not only to identify those treatments that provide a good response for the patient, but also to decrease unnecessary associated toxicities.

Patient-derived tumor organoids grown in culture are a feasible and fast way to study a big array of drugs. However, there was a latent need for a deeper characterization of this novel tool to confirm that it could be of real use in the clinic.

With this aim in mind, Dr. Deming and colleagues have recently published a study in which they compared primary tumor samples versus patient-derived organoids at different levels. In this study, they observed that the histology was similar and they also observed that primary tumor characteristics and mutation profiles were highly conserved. Most importantly, this model predicts with high accuracy and sensitivity if the primary tumors are going to respond to chemotherapy and radio treatments, avoiding unnecessary treatments for the patients.

In parallel, other groups are already using CRISPR-Cas9 technology to eliminate the resistance observed in the organoids and personalized evermore the treatment for the patient.